⌘K

16:00:10·1568d

13D/GFilingvia Quantisnow

SEC Form SC 13G/A filed by Atea Pharmaceuticals Inc. (Amendment)

ByQuantisnow·Wall Street's wire, on your screen.

AVIR· Atea Pharmaceuticals Inc.

Health Care

Original source

Quantisnowquantisnow.com

Quantisnow streams SEC filings, FDA approvals, analyst ratings, insider trades, and press releases to retail investors in real time. This insight was curated and delivered from the Quantisnow live feed.

Related

Atea Pharmaceuticals Presents New Drug-Drug Interaction Results Supporting Potential Best-in-Class Profile of the Regimen of Bemnifosbuvir and Ruzasvir for the Treatment of Hepatitis C Virus at EASL Congress 2026
Amendment: Director Murphy Polly A. bought $25,446 worth of shares (6,100 units at $4.17), increasing direct ownership by 7% to 92,145 units (SEC Form 4)
Director Murphy Polly A. bought $25,446 worth of shares (6,100 units at $4.17), increasing direct ownership by 7% to 92,145 units (SEC Form 4)
Atea Pharmaceuticals to Present Three Abstracts at EASL 2026 Congress Highlighting Progress Across Viral Hepatitis Pipeline
SEC Form 10-Q filed by Atea Pharmaceuticals Inc.